MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Subscribe to see MaxCyte, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
MaxCyte, Inc. is a biotech company headquartered in Rockville, United States. It is publicly listed (MXCT) with a market capitalisation of $107.3M. Xcout tracks 16 named people at MaxCyte, Inc., including Maher Masoud (President, Chief Executive Officer & Executive Director). Xcout recorded 1 job posting from MaxCyte, Inc. in the last 90 days.
10 more named people on record for MaxCyte, Inc., with roles, board committees and tenure — see the full roster →
Xcout recorded 1 job posting from MaxCyte, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see MaxCyte, Inc.'s hiring signals →
A few of MaxCyte, Inc.'s closest competitors — see the full list of competitors and alternatives →
Kytopen Corp. is a biotechnology company focused on cell therapy discovery, with facilities located in Cambridge, Massachusetts, and Louisville, Colorado, as well as an international expansion in Germany.
DeepCyte Inc. is an AI-powered biotechnology and toxicology platform headquartered in Wilmington, Delaware. Established in 2025, the company develops advanced computational tools for toxicity assessment and life sciences research.
Headquartered in Frederick, Maryland, RoosterBio, Inc. is a biotechnology company focused on accelerating human mesenchymal stem cell (hMSC) and exosome product development and biomanufacturing.
CytoTronics is a biotechnology research company headquartered in Boston, Massachusetts, specializing in cell-based discovery and high-density electrode array technology.
CellBri is a cell therapy automation company that develops closed-system, cGMP-ready platforms for manufacturing CAR-T, NK, TCR-T, and stem cells without vendor lock-in.
Avenue Biosciences provides a machine learning-powered protein engineering platform designed to optimize secretory pathways for therapeutic protein manufacturing. The company serves biotechnology and pharmaceutical developers by enhancing the yield, quality, and production of difficult-to-express proteins, biologics, and gene therapies.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.